These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34027269)

  • 1. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial.
    Gawrieh S; Wilson LA; Yates KP; Cummings OW; Vilar-Gomez E; Ajmera V; Kowdley KV; Rosenberg WM; Tonascia J; Chalasani N
    Hepatol Commun; 2021 May; 5(5):786-797. PubMed ID: 34027269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
    Gawrieh S; Harlow KE; Pike F; Yates KP; Wilson LA; Cummings OW; Rosenberg WM; Chalasani N; Molleston JP
    J Pediatr; 2021 Dec; 239():161-167.e5. PubMed ID: 34400208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
    Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
    JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
    Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.
    Chen C; Wang L; Wu J; Lu M; Yang S; Ye W; Guan M; Liang M; Zou H
    Front Pharmacol; 2022; 13():805708. PubMed ID: 35177989
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
    J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
    Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
    Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
    Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
    Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
    Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease.
    Yates KP; Deppe R; Comerford M; Masuoka H; Cummings OW; Tonascia J; Chalasani N; Vuppalanchi R;
    PLoS One; 2017; 12(11):e0185813. PubMed ID: 29095942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
    Corey KE; Wilson LA; Altinbas A; Yates KP; Kleiner DE; Chung RT; Krauss RM; Chalasani N;
    Aliment Pharmacol Ther; 2019 May; 49(9):1205-1213. PubMed ID: 30854694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
    JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
    Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
    J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer.
    Palladino A; Gee M; Shalhoub V; Kiaei D
    Clin Chim Acta; 2023 Aug; 548():117461. PubMed ID: 37390944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
    Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
    Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis.
    Sanyal A; Shankar S; Yates K; Bolognese J; Daly E; Dehn C; Neuschwander-Tetri B; Kowdley K; Vuppalanchi R; Behling CA; Tonascia J; Samir A; Sirlin C; Sherlock S; Fowler K; Heymann H; Kamphaus T; Loomba R; Calle R
    Res Sq; 2023 Jan; ():. PubMed ID: 36711803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
    Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
    Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.